Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
P. Bonniaud (Dijon, France), V. Cottin (Lyon, France), P. Spagnolo (Padova, Italy), M. Nolin (Lyon, France), F. Dalon (Lyon, France), K. Kirchgässler (Basel, Switzerland), J. Chia (South San Francisco, United States of America), T. Kamath (South San Francisco, United States of America), E. Van Ganse (Lyon, France), M. Belhassen (Lyon, France)
Source: Virtual Congress 2020 – Management of chronic lung conditions
Session: Management of chronic lung conditions
Session type: E-poster session
Number: 1673
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Bonniaud (Dijon, France), V. Cottin (Lyon, France), P. Spagnolo (Padova, Italy), M. Nolin (Lyon, France), F. Dalon (Lyon, France), K. Kirchgässler (Basel, Switzerland), J. Chia (South San Francisco, United States of America), T. Kamath (South San Francisco, United States of America), E. Van Ganse (Lyon, France), M. Belhassen (Lyon, France). Healthcare resource use and related costs in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis. 1673
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: